Lincoln Pharmaceuticals Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
LINCOLN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lincoln Pharmaceuticals has submitted a certificate to the stock exchange as required under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. This certificate is routinely filed by the company's Registrar and Share Transfer Agent (RTA) to confirm that share certificates received for dematerialization have been properly cancelled, and certificates issued for rematerialization have been dispatched to shareholders. The filing is a standard compliance requirement and does not involve any corporate action, financial change, or business update. No key financial numbers, dates of effect, or transactional details are mentioned in the announcement.
This is a routine regulatory filing with no material impact on shareholders or the stock price. It reflects normal operational compliance by the company's RTA regarding share dematerialization and rematerialization activities.